A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase III Study to Assess the Efficacy and Safety of Lu AA21004 in Patients With Major Depressive Disorder.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase III Study to Assess the Efficacy and Safety of Lu AA21004 in Patients With Major Depressive Disorder.

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Nov 2017

At a glance

  • Drugs Vortioxetine (Primary)
  • Indications Major depressive disorder
  • Focus Registrational; Therapeutic Use
  • Sponsors Takeda
  • Most Recent Events

    • 12 Nov 2017 Results of a short-term study (NCT01355081) and its long-term extension study (NCT01395147), published in the Psychiatry and Clinical Neurosciences Journal.
    • 23 May 2016 New source identified and integrated (Japan Pharmaceutical Information Center - Clinical Trials Information; JapicCTI111492)
    • 01 Dec 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov record (Parent trial: NCT01355081).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top